Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCB099318 |
Synonyms | |
Therapy Description |
INCB099318 inhibits PD-L1 (CD274), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB099318 | INCB-099318|INCB 099318|INCB99318|INCB 99318|INCB-99318 | Immune Checkpoint Inhibitor 149 PD-L1 Inhibitor 13 | INCB099318 inhibits PD-L1 (CD274), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04272034 | Phase I | INCB099318 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | Terminated | USA | SWE | NOR | GBR | FIN | DNK | BEL | 0 |